+Compare
MRUS
Stock ticker:
NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
1.12B

MRUS Merus NV Forecast, Technical & Fundamental Analysis

a developer of therapeutics for cancer treatment

Industry Biotechnology
GET INTRADAY SIGNALS
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for MRUS with price predictions
08:00 PM EDT Jun 01, 2023

MRUS sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for MRUS moved above the 200-day moving average on May 04, 2023. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 67 cases where MRUS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on May 31, 2023. You may want to consider a long position or call options on MRUS as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for MRUS just turned positive on June 01, 2023. Looking at past instances where MRUS's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

MRUS moved above its 50-day moving average on May 05, 2023 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for MRUS crossed bullishly above the 50-day moving average on May 10, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MRUS advanced for three days, in of 274 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRUS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

MRUS broke above its upper Bollinger Band on June 01, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. MRUS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.149) is normal, around the industry mean (24.947). P/E Ratio (0.000) is within average values for comparable stocks, (122.964). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.308). Dividend Yield (0.000) settles around the average of (0.031) among similar stocks. P/S Ratio (23.641) is also within normal values, averaging (307.036).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Sorrento Therapeutics (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.11B. The market cap for tickers in the group ranges from 365 to 360.75B. NONOF holds the highest valuation in this group at 360.75B. The lowest valued company is CLAZF at 365.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 2%. For the same Industry, the average monthly price growth was 43%, and the average quarterly price growth was 52%. EFTR experienced the highest price growth at 77%, while CLXT experienced the biggest fall at -77%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -45%. For the same stocks of the Industry, the average monthly volume growth was -57% and the average quarterly volume growth was -71%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 50
SMR Rating: 93
Profit Risk Rating: 94
Seasonality Score: 7 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published Earnings

MRUS is expected to report earnings to rise 2.07% to -87 cents per share on August 03

Merus NV MRUS Stock Earnings Reports
Q2'23
Est.
$-0.88
Q1'23
Beat
by $0.16
Q4'22
Missed
by $0.88
Q3'22
Beat
by $0.08
Q2'22
Beat
by $0.49
The last earnings report on May 04 showed earnings per share of -86 cents, beating the estimate of -101 cents. With 159.47K shares outstanding, the current market capitalization sits at 1.12B.
A.I. Advisor
published General Information

General Information

a developer of therapeutics for cancer treatment

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
Uppsalalaan 17
Phone
+31 302538800
Employees
221
Web
https://www.merus.nl
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AZMPX15.31N/A
N/A
Virtus NFJ Emerging Markets Value P
JRARX56.58N/A
N/A
Janus Henderson Research R
PNRZX50.57N/A
N/A
PGIM Jennison Natural Resources Z
RTIRX9.67N/A
N/A
Russell Inv Multifactor Intl Eq R6
TSMGX13.24N/A
N/A
Touchstone Sands Cptl Emerg Mkts Gr A

MRUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, MRUS has been loosely correlated with NRIX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MRUS jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRUS
1D Price
Change %
MRUS100%
+3.55%
NRIX - MRUS
45%
Loosely correlated
+0.49%
NTLA - MRUS
41%
Loosely correlated
+2.42%
SRNEQ - MRUS
40%
Loosely correlated
+0.22%
EDIT - MRUS
40%
Loosely correlated
+4.03%
MDGL - MRUS
40%
Loosely correlated
-3.37%
More

Groups containing MRUS

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRUS
1D Price
Change %
MRUS100%
+3.55%
cancer
(undefined stocks)
39%
Loosely correlated
+2.17%
treatment
(undefined stocks)
35%
Loosely correlated
+2.16%
drugs
(undefined stocks)
34%
Loosely correlated
+1.51%
biotechnology
(undefined stocks)
32%
Poorly correlated
+1.47%
europe
(undefined stocks)
26%
Poorly correlated
+2.19%
More